The Kura Oncology Inc. (KURA) Receives Outperform Rating from Leerink Swann

The Kura Oncology Inc. (KURA) Receives Outperform Rating from Leerink Swann

Leerink Swann reaffirmed their outperform rating on shares of Kura Oncology Inc. (NASDAQ:KURA) in a report released on Thursday morning. The brokerage currently has a $15.00 price objective on the stock.

A number of other analysts also recently weighed in on KURA. Oppenheimer Holdings Inc. reiterated an outperform rating and issued a $16.00 price target on shares of Kura Oncology in a research report on Tuesday, June 21st. Zacks Investment Research upgraded shares of Kura Oncology from a hold rating to a buy rating and set a $3.75 target price on the stock in a report on Wednesday, July 13th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $14.15.

Kura Oncology (NASDAQ:KURA) traded down 0.35% during mid-day trading on Thursday, hitting $5.74. The stock had a trading volume of 3,270 shares. The company’s market cap is $107.58 million. Kura Oncology has a one year low of $2.50 and a one year high of $25.00. The company has a 50 day moving average price of $6.15 and a 200-day moving average price of $4.19.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. Equities analysts expect that Kura Oncology will post ($1.58) earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Kura Oncology stock. Minerva Advisors LLC bought a new stake in Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent filing with the SEC. The firm bought 361,737 shares of the company’s stock, valued at approximately $977,000. Minerva Advisors LLC owned approximately 1.96% of Kura Oncology as of its most recent filing with the SEC. 43.63% of the stock is currently owned by institutional investors.

About Kura Oncology

Related posts

Leave a Comment